Interesting that they are going to use both Lipitor and Crestor. I remind everyone that the MACE effects were seen across the board even though some of the synergism between Crestor and 208 were evident from other data. Patience is going to be key going forward but the getting FDA approval to start Phase 3 is the main driver in my eyes. BARCELONA, Spain and CALGARY, AB, Sept. 2, 2014 /CNW/ - Resverlogix Corp. (TSX: RVX) announced today that Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix delivered an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Spain. In his presentation, entitled: 'Effects of RVX-208 on MACE, ApoA-I and HDLs; a post-hoc analysis from the pooled SUSTAIN and ASSURE clinical trials', Dr. Johansson reported that patients with cardiovascular disease (CVD) arising from atherosclerosis when given RVX-208 had a 55% (p=0.02) relative risk reduction (RRR) in MACE. More importantly, this beneficial effect of RVX-208 on patients with diabetes mellitus was accentuated with a RRR in MACE that was lowered by 77% (p=0.01). These observed reductions in MACE may stem from the ability of RVX-208 to significantly improve specific biomarkers of CVD risk measured in the SUSTAIN and ASSURE trials, including: higher levels of ApoA-I protein (p<0.05). The significant improvement in these biomarkers was in treated patients vs. placebo, which point to the beneficial effects of RVX-208 on reverse cholesterol transport.